| A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease SR Targan, SB Hanauer, SJH Van Deventer, L Mayer, DH Present, ... New England Journal of Medicine 337 (15), 1029-1036, 1997 | 4158 | 1997 |
| Infliximab for the treatment of fistulas in patients with Crohn's disease DH Present, P Rutgeerts, S Targan, SB Hanauer, L Mayer, ... New England Journal of Medicine 340 (18), 1398-1405, 1999 | 3542 | 1999 |
| Infliximab maintenance therapy for fistulizing Crohn's disease BE Sands, FH Anderson, CN Bernstein, WY Chey, BG Feagan, ... New England Journal of Medicine 350 (9), 876-885, 2004 | 2837 | 2004 |
| Polyp miss rate determined by tandem colonoscopy: a systematic review JC Van Rijn, JB Reitsma, J Stoker, PM Bossuyt, SJ Van Deventer, ... Official journal of the American College of Gastroenterology| ACG 101 (2 …, 2006 | 1649 | 2006 |
| Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial G D'Haens, F Baert, G Van Assche, P Caenepeel, P Vergauwe, ... The Lancet 371 (9613), 660-667, 2008 | 1482 | 2008 |
| Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2) HM Van Dullemen, SJH van Deventer, DW Hommes, HA Bijl, J Jansen, ... Gastroenterology 109 (1), 129-135, 1995 | 1450 | 1995 |
| Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations J Hampe, A Cuthbert, PJP Croucher, MM Mirza, S Mascheretti, S Fisher, ... The Lancet 357 (9272), 1925-1928, 2001 | 1431 | 2001 |
| Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease P Rutgeerts, G D'Haens, S Targan, E Vasiliauskas, SB Hanauer, ... Gastroenterology 117 (4), 761-769, 1999 | 1345 | 1999 |
| Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways SJ Van Deventer, HR Buller, JW ten Cate, LA Aarden, CE Hack, A Sturk | 1184 | 1990 |
| Natalizumab induction and maintenance therapy for Crohn's disease WJ Sandborn, JF Colombel, R Enns, BG Feagan, SB Hanauer, ... New England Journal of Medicine 353 (18), 1912-1925, 2005 | 1069 | 2005 |
| A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease H Braat, P Rottiers, DW Hommes, N Huyghebaert, E Remaut, JP Remon, ... Clinical gastroenterology and hepatology 4 (6), 754-759, 2006 | 967 | 2006 |
| Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial G D'Haens, S Van Deventer, R Van Hogezand, D Chalmers, C Kothe, ... Gastroenterology 116 (5), 1029-1034, 1999 | 959 | 1999 |
| Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease JMH Van den Brande, H Braat, GR Van Den Brink, HH Versteeg, ... Gastroenterology 124 (7), 1774-1785, 2003 | 916 | 2003 |
| Activation of coagulation after administration of tumor necrosis factor to normal subjects T Van Der Poll, HR Büller, H Ten Cate, CH Wortel, KA Bauer, ... New England Journal of Medicine 322 (23), 1622-1627, 1990 | 840 | 1990 |
| Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease T Ten Hove, C Van Montfrans, MP Peppelenbosch, SJH Van Deventer Gut 50 (2), 206-211, 2002 | 734 | 2002 |
| Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease RN Fedorak, A Gangl, CO Elson, P Rutgeerts, S Schreiber, G Wild, ... Gastroenterology 119 (6), 1473-1482, 2000 | 714 | 2000 |
| Mucosal tumor necrosis factor-or, interleukin-1/3, and interleukin-8 production in patients with helicobacter pylori infection LA Noach, NB Bosma, J Jansen, FJ Hoek, SJH Van Deventer, GNJ Tytgat Scandinavian journal of gastroenterology 29 (5), 425-429, 1994 | 676 | 1994 |
| Tumour necrosis factor and Crohn's disease SJ Van Deventer Gut 40 (4), 443, 1997 | 675 | 1997 |
| Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease S Schreiber, RN Fedorak, OH Nielsen, G Wild, CN Williams, S Nikolaus, ... Gastroenterology 119 (6), 1461-1472, 2000 | 658 | 2000 |
| Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets DW Hommes, MP Peppelenbosch, SJH Van Deventer Gut 52 (1), 144-151, 2003 | 645 | 2003 |
Cornelis Erik HackHoogleraar Immunologie, Universitair Medisch Centrum UtrechtVerified email at Umcutrecht.nl
Stefan SchreiberKielVerified email at mucosa.deHugo ten CateProfessor of Medicine, Maastricht University Medical CenterVerified email at maastrichtuniversity.nl
P.H. ReitsmaEinthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, LeidenVerified email at lumc.nl
James C H HardwickLeiden University Medical Center, Leiden, The NetherlandsVerified email at lumc.nl
Bruce E. SandsIcahn School of Medicine at Mount SinaiVerified email at mssm.edu
William SandbornUniversity of California San DiegoVerified email at ucsd.edu
Prof. Marcus J. SchultzAmsterdam, Vienna, Oxford and Bangkok Universities (amsterdamumc.nl amc.nl amc.uva.nl uva.nl)Verified email at amc.uva.nl
Anna MajowiczuniQure, AmsterdamVerified email at uniqure.com
Jochen HampeTechnische Universität Dresden (TU Dresden)Verified email at uniklinikum-dresden.de
Ric van TolProgram Director at TNOVerified email at rb.com
